文献速递淋巴瘤

联合抑制EZH2与DOT1L在B细胞淋巴瘤中的协同抗肿瘤效应

Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma.
PubMed 文献 · Blood · 2025-01-01

研究在B细胞淋巴瘤细胞中进行CRISPR/Cas9敲除筛选,发现组蛋白甲基转移酶DOT1L为潜在治疗靶点;EZH2抑制剂与DOT1L抑制剂在多种B细胞淋巴瘤细胞系中协同作用,不依赖EZH2突变状态,并在异种移植模型中显著抑制肿瘤生长。

要点

  • EZH2抑制剂与DOT1L抑制剂在B细胞淋巴瘤细胞系中协同,不依赖EZH2突变状态。
  • 两药协同抑制DOT1L调控的细胞周期基因,上调干扰素信号及抗原呈递基因。
  • 异种移植模型中联合策略显著抑制肿瘤生长,提供临床前概念验证。

核心结论

  • 研究为表观遗传联合治疗克服耐药、提高B细胞淋巴瘤缓解持久性提供临床前概念验证,值得临床研究。

研究设计与样本

  • 在B细胞淋巴瘤细胞中行CRISPR/Cas9敲除筛选,分别在有或无EZH2抑制剂处理条件下进行。

主要发现

  • EZH2抑制剂与DOT1L抑制剂在多种B细胞淋巴瘤细胞系中协同,无论EZH2突变状态如何。
  • 两抑制剂协同抑制DOT1L调控的细胞周期基因,上调干扰素信号相关基因包括抗原呈递基因,并通过去阻遏EZH2调控的浆细胞特征基因驱动B细胞分化。
  • 异种移植模型中联合策略显著抑制肿瘤生长。

局限性

  • 原文指出需进行临床研究(warranting clinical investigation)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the approval of several new treatments for patients with B-cell lymphoma, there is still a large unmet need. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the 2 most common B-cell lymphoma subtypes, accounting for ∼50% of all cases. EZH2 heterozygous gain-of-function somatic driver mutations are frequently found in germinal center B-cell DLBCLs and FLs. An EZH2 inhibitor has shown durable responses in patients with relapsed or refractory FL, however a considerable fraction of the patients did not show an objective response. To identify alternative therapeutic strategies, we performed CRISPR/Cas9 knockout screens in B-cell lymphoma cells treated with or without an EZH2 inhibitor. This led to the identification of the histone methyltransferase DOT1L as a potential therapeutic target. Specifically, we showed that an EZH2 inhibitor synergizes with a DOT1L inhibitor in a panel of B-cell lymphoma cell lines regardless of the EZH2 mutation status. Mechanistically, we demonstrated that the 2 inhibitors cooperatively suppress DOT1L-regulated cell cycle genes, upregulate genes involved in interferon signaling, including antigen presenting genes, and ultimately drive B-cell differentiation by derepressing EZH2-regulated plasma cell signature genes. Furthermore, we demonstrated the effectiveness of this epigenetic combination strategy in a xenograft model, which led to significant abrogation of tumor growth. Together, our studies provide preclinical proof-of-concept for an epigenetic combination therapy to overcome resistance and improve durability of response for the treatment of B-cell lymphoma, warranting clinical investigation and illustrating an important convergent role of EZH2 and DOT1L in B-cell lymphomagenesis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nguyen VTM, Namba H, Porter H, et al. Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma. Blood. 2025. PMID: 40009485. doi:10.1182/blood.2024026534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。